SEC Filings TLDR Banner

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.

Filter by Form Type:
All346-K8-K10-Q144Schedule 13GSchedule 13G/ASchedule 13DSchedule 13D/A
Industry:Biotechnologyβœ•
Previous Page123456Next Page
2026-05-01HEPASCHEDULE 13DVincent LoPriore Discloses 21.46% Stake in Hepion Pharmaceuticals, Inc. via Schedule 13DHIGH
On May 1, 2026, Vincent LoPriore, the Executive Chairman of Hepion Pharmaceuticals, Inc. (HEPA), filed a Schedule 13D disclosing a significant new ownership stake in the company. As of the event date on April 21, 2026, LoPriore beneficially owns 6,250,000 shares of Common Stock, representing 21.46% of the class. This p...
Biotechnologyownership +21.46%
2026-05-01XOMASCHEDULE 13DLigand Pharmaceuticals to Acquire XOMA Royalty Corp via Merger and Support AgreementsHIGH
On April 27, 2026, Ligand Pharmaceuticals Incorporated entered into an Agreement and Plan of Merger to acquire XOMA Royalty Corporation. Under the terms of the agreement, Ligand's subsidiary, Flex Merger Sub, Inc., will merge with and into a newly formed holding company of XOMA, with XOMA surviving as a wholly owned su...
Small CapBiotechnologyownership +47.00%
2026-05-01Hepion Pharmaceuticals, Inc.SCHEDULE 13DVincent LoPriore Discloses 21.46% Stake in Hepion Pharmaceuticals, Inc. via Schedule 13DDuplicateHIGH
On May 1, 2026, Vincent LoPriore, the Executive Chairman of Hepion Pharmaceuticals, Inc. (HEPA), filed a Schedule 13D disclosing a significant new ownership stake in the company. As of the event date on April 21, 2026, LoPriore beneficially owns 6,250,000 shares of Common Stock, representing 21.46% of the class. This p...
Biotechnologyownership +21.46%
2026-05-01LIGAND PHARMACEUTICALS INCSCHEDULE 13DLigand Pharmaceuticals to Acquire XOMA Royalty Corp via Merger and Support AgreementsDuplicateHIGH
On April 27, 2026, Ligand Pharmaceuticals Incorporated entered into an Agreement and Plan of Merger to acquire XOMA Royalty Corporation. Under the terms of the agreement, Ligand's subsidiary, Flex Merger Sub, Inc., will merge with and into a newly formed holding company of XOMA, with XOMA surviving as a wholly owned su...
Small CapBiotechnologyownership +47.00%
2026-04-27ACHVSCHEDULE 13DvenBio Global Strategic Fund V Acquires 9.99% Stake in Achieve Life Sciences via Private PlacementHIGH
On April 15, 2026, venBio Global Strategic Fund V, L.P. and venBio Global Strategic GP V, LLC (the Reporting Persons) entered into a Securities Purchase Agreement with Achieve Life Sciences, Inc. (ACHV). Through a private placement, venBio acquired 5,914,720 shares of Common Stock and 5,914,720 Common Warrants for a to...
Micro CapBiotechnologyownership +9.99%
Previous Page123456Next Page